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Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G), 
a cytidine deaminase, is a recently recognized innate intracellular protein with lethal activity 
against human immunodefi  ciency virus (HIV). Packaged into progeny virions, APOBEC3G 
enzymatic activity leads to HIV DNA degradation. As a counterattack, HIV virion infectivity 
factor (Vif) targets APOBEC3G for proteasomal proteolysis to exclude it from budding 
virions. Based on the ability of APOBEC3G to antagonize HIV infection, considerable 
interest hinges on elucidating its mechanism(s) of regulation. In this study, we provide the 
fi  rst evidence that an innate, endogenous host defense factor has the potential to promote 
APOBEC3G and rebuke the virus-mediated attempt to control its cellular host. We identify 
interferon (IFN)-𝗂 as a potent inducer of APOBEC3G to override HIV Vif neutralization of 
APOBEC3 proteins that pose a threat to effi  cient macrophage HIV replication. Our data 
provide a new dimension by which IFN-𝗂 mediates its antiviral activity and suggest a 
means to render the host nonpermissive for viral replication.
Identifi  ed as an HIV virion infectivity factor 
(Vif) target through subtracted cloning be-
tween permissive and nonpermissive cell lines 
to Vif-defi  cient HIV (1), cellular  apolipoprotein 
B mRNA-editing enzyme-catalytic polypeptide-
like 3G (APOBEC3G) is packaged into new 
viral particles during viral synthesis to combat 
infectivity. APOBEC3G deaminates deoxycy-
tidine to deoxyuridine of minus single–strand 
nascent viral DNA during reverse transcrip-
tion, which results in hypermutation of plus-
strand DNA. This enzymatic editing of HIV 
reverse transcripts leads to degradation of de-
aminated minus-strand DNA (2–4) and block-
ade of HIV replication, although nonenzymatic 
antiretroviral mechanisms for APOBEC3G have 
recently been invoked (5, 6). To circumvent this 
protective role of host cell APOBEC3G, Vif 
binds to APOBEC3G, targeting it for protea-
some-dependent proteolysis (7–9) or alternative 
modes of inactivation (5), and in most cases, 
HIV Vif triumphs over cellular APOBEC3G. 
Despite the susceptibility of HIV to restriction 
by this species-specifi  c   innate and constitutively 
expressed path-way (9), little is known regard-
ing the existence of regulatory mechanisms by 
which to embellish APOBEC3G and/or its re-
lated mammalian family of cytidine deaminases 
to dest  abilize retroviral genomes and potentially 
thwart infection.
IFN-α is a potent inhibitor of HIV infec-
tion in CCR5+CD4+ human macrophages 
(10, 11), which in addition to CD4+ T cells, 
represent major hosts of HIV (12). IFN-α exerts 
its antiviral activity through multiple mecha-
nisms, including the RNA-dependent protein 
kinase (PKR)/eukaryotic initiation factor 2 α 
pathway, oligoadenylate synthetase/RNaseL 
pathway, and myxovirus resistance GTPase. 
Activated PKR phosphorylates multiple sub-
strates, including itself, eukaryotic initiation 
factor 2 α, and IκBα to mediate not only 
antiviral activity, but also apoptosis and anti-
infl  ammatory actions (13, 14). IFN-α induc-
tion of an RNA-specifi  c adenosine deaminase, 
which catalyzes adenosine to inosine in both 
viral RNA and cellular pre-mRNA to cause 
hypermutation, may also antagonize infection 
(13) and suggests a potential infl  uence on other 
deaminases. Although the role of APOBEC3 
proteins in macrophage HIV infection has re-
ceived less emphasis than in T cells, we examined 
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the possibility that IFN-α may infl  uence APOBEC3G in as-
sociation with its potent antiretroviral activity in these hosts. 
Using an in vitro primary human macrophage system, we de-
fi  ne an IFN-specifi  c up-regulation of APOBEC3G in associa-
tion with inhibition of HIV, off  ering insight into reversing sus-
ceptibility to infection by manipulation of this family of innate 
resistance factors.
RESULTS AND DISCUSSION
IFN-𝗂 enhances APOBEC3G
Human primary monocyte–derived macrophages express low 
levels of APOBEC3G (Fig. 1 A), consistent with a cell nonper-
missive to HIV in the absence of Vif (1). To determine whether 
IFN-α directly infl   uences APOBEC3G expression, macro-
phages were treated with IFN-α and by RT-PCR; a dose-de-
pendent increase in APOBEC3G gene expression was detected 
(Fig. 1 A). A kinetic analysis revealed that a single treatment 
with 10 ng/ml IFN-α enhanced APOBEC3G gene expression 
within 1 h, which increased further at 4 h (Fig. 1 B). PKR 
gene expression and activation are prominent consequences of 
IFN activity (13), and a similar time-dependent pattern of gene 
expression was observed in macrophages treated with IFN-α 
for both APOBEC3G and PKR by RT-PCR (Fig. 1 B), and 
APOBEC3G expression was confi   rmed by real-time PCR 
(Fig. 1 C). A corresponding IFN-α–induced increase in APO-
BEC3G protein was evident in macrophage lysates by Western 
blot using a monoclonal anti-APOBEC3G antibody (Fig. 
1 D). Thus, by both RNA and protein analyses, IFN-α was 
able to induce elevated APOBEC3G in primary macrophages. 
This IFN-α response was consistent, although variable baseline 
levels of APOBEC3G were donor dependent. Furthermore, 
2-aminopurine (2-AP), a PKR inhibitor in macrophages (15), 
suppressed IFN-α–induced APOBEC3G mRNA to basal lev-
els (Fig. 1 A) with a subsequent reduction in protein expression 
(Fig. 1 D), suggesting that APOBEC3G   expression may be 
downstream of PKR activation. Collectively, these data in-
dicate that IFN-α achieves APOBEC3G augmentation by 
  promoting gene expression rather than inhibiting proteasome-
dependent degradation and that there isa connecting link 
  between PKR and APOBEC3G.
IFN-𝗂 reverses HIV suppression of APOBEC3G
Because IFN-α impedes HIV infection in macrophages (13), 
induced APOBEC3G may represent a previously unrecognized 
mechanism underlying this antiviral activity. Associated with the 
dose-dependent enhancement of APOBEC3G (Fig. 1), IFN-α 
blocked HIV infection (Fig. 2 A). Although HIV typically sup-
pressed APOBEC3G protein levels (Fig. 2 B, inset, day 3), 
consistent with the fact that Vif promotes APOBEC3G degra-
dation, the addition of IFN-α reversed the loss of APOBEC3G 
protein in the infected cultures, coincident with reduced viral 
replication (Fig. 2 B). Whether the emergence of low APO-
BEC3G expression around 7 d after infection refl  ects dimin-
ished proteasomal degradation, endogenous IFN-α release (16), 
and/or other sequelae, increased APOBEC3G in IFN-α–
treated infected macrophages remained consistent with 
  restricted HIV expansion (Fig. 2 B). In virus-free cells, 
APOBEC3G levels characteristically diminish with time in 
culture. The infl  uence of IFN-α on HIV infection in macro-
phages appears to occur early in the viral life cycle. For ex-
ample, a single treatment may prevent productive HIV in
fection for up to 7 d, compatible with targeting of an event(s) 
Figure 1.  IFN-𝗂 induces APOBEC3G expression. (A) Macrophages 
were not treated (control) or treated with 1–100 ng/ml IFN-α for 18 h in 
the absence or presence of 1 mM 2-AP, and RNA was analyzed for APO-
BEC3G by RT-PCR (30 cycles). (B) Macrophages were treated or not with 
10 ng/ml IFN-α for the indicated times, and RNA was subjected to RT-PCR 
to amplify APOBEC3G and PKR mRNA. Representative experiment, n = 3. 
(C) Macrophages were treated with IFN-α for 2–16 h, and APOBEC3G 
expression was assessed by real-time PCR as compared with untreated 
cells cultured in parallel. Data (mean ± SD of triplicates) are presented as 
fold change from 2-h control macrophages. (D) Cell lysates were obtained 
after macrophage treatment with 10 ng/ml IFN-α and/or 1 mM 2-AP and 
assessed for APOBEC3G protein ( 42 kD) by Western blot.
Figure 2.  IFN-𝗂 increases APOBEC3G coincident with anti-HIV 
activity. (A) Dose-dependent inhibition of HIV infection by a single addi-
tion of 0–50 ng/ml IFN-α immediately after macrophage (48-well plates) 
cultures were exposed to HIV for 2 h and washed to remove free virus. 
Supernatant p24 levels were measured on day 5. n = 3, mean ± SD; 
*, P < 0.001. (B) Macrophages (six-well plates) were infected with HIV, and 
10 ng/ml IFN-α was added after infection and added back every 2–3 d. 
p24 levels were measured in the supernatants. Inset: APOBEC3G was de-
tected in lysates of macrophages infected with HIV in the presence or 
absence of IFN-α 3 and 7 d after infection by Western blot (n = 2).JEM VOL. 203, January 23, 2006  43
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in the virus life cycle before massive replication. An early in-
crease of APOBEC3G by IFN-α likely promotes enhanced 
APOBEC3G packaging into the initial viral particles, which 
in turn renders these virions defective in establishing new 
rounds of infection.
IFN uniquely regulates APOBEC3G
To establish whether IFN-α was a unique regulator of this 
antiviral molecule in macrophages, we analyzed a panel of 
cytokines for their ability to alter the expression profi  le of 
APOBEC3G protein. As shown in Fig. 3 A, of the cytokines 
evaluated, only IFN-α and IFN-γ were found to detectably 
enhance this retroviral restrictor, whereas the remaining in-
fl  ammatory mediators (TNF-α, IL-1β, IL-8, MCP-1, RAN-
TES, and TGF-β) tested did not promote APOBEC3G 
production nor augment PKR. Although only a limited 
number of proteins were analyzed and other potential in-
ducers cannot be excluded, since its recent discovery, there 
has yet to be any report of APOBEC3G induction by other 
endogenous factors. Moreover, because IFN-α was report-
edly ineff  ective in enhancing APOBEC3G expression in a 
T cell line (17) and did not increase frequency of G to A 
hyper  mutations in hepatitis B virus stably infected HepG2 
cell lines (18), this may represent a key macrophage anti-
viral pathway.
IFN-𝗂 and IFN-𝗄 collaboratively increase APOBEC3G 
and inhibit HIV
Because both IFN-α and IFN-γ increase APOBEC3G and 
inhibit HIV infection in macrophages, and macrophages re-
main a crucial target and reservoir of HIV in the blood even 
after HAART (19, 20) as well as in the tissues (21), we sought 
to determine the relative effi   ciency of the IFNs on their in-
nate cellular defenses. Although IFN-α is clinically eff  ective 
against HIV and multiple additional viruses, its toxicity repre-
sents a clinical concern (22). By comparison, IFN-γ, func-
tioning as an immune stimulant, has both anti–HIV-1 and 
PKR activation potential, but to a lesser extent than IFN-α 
(13). To test the possibility that IFN-γ together with IFN-α 
might enable use of reduced levels of IFN-α, while achieving 
a comparable antiviral eff  ect, we compared IFN-α and IFN-γ 
concentrations required for inhibition of HIV. IFN-α was 
typically severalfold more potent than IFN-γ in the in vitro 
infection assay. Costimulation with IFN-α and IFN-γ at sub-
optimal concentrations in a single application after viral inoc-
ulation resulted in complete or near complete antiviral activity, 
as compared with treatment with IFN-α or IFN-γ alone 
(Fig. 3 B, day 7 p24 shown). This dual treatment further bol-
stered APOBEC3G (Fig. 3 B, inset) expression that correlated 
with enhanced viral resistance. Nonetheless, as shown in Fig. 
3 C, a single treatment with IFN-α, IFN-γ, or with IFN-α 
plus IFN-γ did not inhibit viral replication indefi  nitely, and 
reexposure to the IFNs was required to sustain APOBEC3G 
and maximum viral suppression beyond 1 wk. Whether ad-
ministered individually or coordinately, these data provide the 
fi  rst indication that APOBEC3G-mediated interference with 
the production of a functional provirus can be regulated by a 
host cytokine as a new point of attack in the viral life cycle.
Preferential regulation of APOBEC3 family genes by IFN-𝗂
APOBEC3 represents a family of deaminase proteins, some 
of which reportedly restrict HIV infection (APOBEC3G and 
APOBEC3F) or are infl  uenced by IFN (APOBEC3A; refer-
ences 23–26), and we examined whether IFN-α could trigger 
the expression of additional superfamily genes. In macro-
phages from multiple donors, RT-PCR showed that IFN-α 
not only up-regulated APOBEC3G, but also APOBEC3A 
and APOBEC3F with a similar profi  le. Family members 
APOBEC3B and APOBEC3C were not consistently aug-
mented by IFN-α (Fig. 4 A, two representative donors shown). 
Consequently, IFN-α appears to preferentially regulate mem-
bers of the APOBEC3 cluster that reportedly have anti- 
viral activity. In this regard, our analysis of the 5′ region of 
Figure 3.  APOBEC3G is inducible by IFN-𝗂 and IFN-𝗄. (A) Macro-
phages were treated with the indicated cytokines at 100 ng/ml or TGFβ 
at 10 ng/ml for 20 h. Induction of APOBEC3G in macrophage lysates was 
examined by Western blot using anti-APOBEC3G and anti-PKR antibodies. 
(B) Macrophages were infected with HIV (104 TCID50), and IFN-α, IFN-γ, or 
combined IFNs (1–10 ng/ml) were added. Infected macrophage superna-
tants were assayed by p24 ELISA. Data shown are mean ± SD; **, P < 0.05; 
*, P < 0.01. Inset: APOBEC3G protein was assayed by Western blot 3 d 
after single or dual IFN treatment (5 ng/ml). (C) Kinetics of HIV infection 
(p24) in macrophages treated only once with IFN at the onset of infection 
(n = 3, mean ± SD).44  IFN INDUCES APOBEC3G | Peng et al. 
APOBEC3 family genes (National Center for Biotechnology 
Information, National Institutes of Health [NIH]) revealed dif-
ferential expression of IFN-stimulated  response elements (ISRE). 
We identifi  ed the existence of an ISRE sequence −47 to −59 
from the APOBEC3G translation start codon (G A  A  A  G  T  G  A  A-
A  C  ), and an identical ISRE sequence is also found in APO-
BEC3F, refl  ecting their   coordinate regulation. A potential 
promoter region in  APOBEC3A, containing an ISRE (−1,787 
to −1,800), is located further from the start codon relative to 
APOBEC3G and is consistent with IFN-α inducibility. Thus, 
our data support several APOBEC3 nucleic acid–editing 
  enzymes (APOBEC3A, APOBEC3F, and APOBEC3G) as 
ISRE-competent IFN-α–inducible targets. Among them, 
both APOBEC3F and APOBEC3G can   reportedly restrain 
Vif-dependent infection mechanisms (1, 24, 25). Although we 
observed that APOBEC3A is also coordinately expressed after 
macrophage exposure to IFN-α, to date, no antiviral activity 
has been ascribed to this family member.
Knockdown of APOBEC3G by small interfering RNA (siRNA) 
blunts inhibition of HIV by IFN-𝗂
IFN-α executes its antiviral activity through multiple mech-
anisms, including PKR and RNase L and/or RNA deami-
nases (13). As our evidence implicates APOBEC3 family 
induction as one of the potential contributing mechanisms, 
we considered that removal of APOBEC3G would result in 
at least a partial block of IFN-α antiviral activity. Using siRNA 
synthesized based on the sequence of APOBEC3G, we show 
that transfection of siRNA into macrophages decreased APO-
BEC3G RNA and protein induction by IFN-α, in contrast 
to control siRNA (Fig. 4, B and C), without any eff  ect on 
IFN-α–induced PKR. When the cells were depleted of 
APOBEC3G by siRNA and then treated with a low dose of 
IFN-α (1 ng/ml), IFN-α could no longer completely inhibit 
HIV in the absence of APOBEC3G (Fig. 5). By comparison, 
the same dose of IFN-α eff  ectively inhibited HIV infection in 
both untransfected and negative control siRNA-transfected 
macrophages (Fig. 5), confi  rming that APOBEC3G is a key 
downstream anti-HIV mechanism induced by IFN-α. Per-
haps not surprisingly, at a higher dose of 10 ng/ml, IFN-α in-
hibition of HIV infection in macrophages was not substantially 
altered by siRNA transfection of APOBEC3G (not depicted), 
likely a result of the multiple antiviral mechanisms triggered 
by IFN-α. Furthermore, by nested PCR, which detects early 
viral de novo DNA synthesis (Fig. 5, inset), it was apparent 
that depletion of APOBEC3G by siRNA resulted in sub-
stantially augmented reverse transcription with elevated lev-
els of HIV proviral DNA (day 2 after exposure to HIVBaL 
shown) once this obstacle was removed.
In what appears to be a unique and powerful pathway, 
IFN-α increases APOBEC3G expression as a component of 
its complex repertoire of antiviral mechanisms. This selective 
induction of APOBEC3G by IFN-α provides a pot  ential 
mechanism to overcome HIV Vif sequestration of  APOBEC3G, 
thus allowing enhanced APOBEC3G packaging into the bud-
ding virions to dampen further infection   potential. The net ef-
fect is that IFN-α tilts the balance   between APOBEC3G and 
Vif in favor of APOBEC3G as opposed to unimpaired Vif-
driven APOBEC3G degradation, which enables HIV replica-
tion in subsequent host cells. Demonstration of IFN-α–inducible 
intracellular APOBEC3G suggests an important strategic ap-
proach to regulation of this newly   recognized intracellular 
  defense against the deadly virus. Beyond the role of APO-
BEC3G in retroviral infections, recent evidence   documents 
Figure 4.  IFN-𝗂 augments induction of APOBEC3 family members. 
(A) RNA was isolated from macrophages (two donors shown) untreated or 
treated with 10 ng/ml IFN-α for 4 h and evaluated by RT-PCR with prim-
ers corresponding to each of the indicated APOBEC3 genes and PKR 
(30 cycles). GAPDH was used as a parallel control. (B) Monocytes were trans-
fected with APOBEC3G siRNA, cultured for 6 d, stimulated with IFN-α for 
4 h, and APOBEC3G and PKR expression was monitored by RT-PCR in 
comparison with the GAPDH control. (C) Western blot for APOBEC3G 
protein 6 d after monocyte transfection with siRNA or control RNA, or 
electroporation only control (EPC), and treatment with or without IFN-α 
for 20 h. Representative experiment, n = 3.
Figure 5.  APOBEC3G siRNA blocks IFN-𝗂 anti-HIV activity. Mono-
cytes were transfected with APOBEC3G siRNA, cultured for 6 d, infected 
with HIV, and treated or not with 1 ng/ml IFN-α. P24 levels were moni-
tored in the supernatants of untreated and treated macrophage cultures 
at the indicated time points after infection with HIV. Inset: Nested PCR to 
evaluate initial rounds of HIV replication (day 2 after infection) in cells 
transfected with APOBEC3G-specifi  c siRNA or negative control siRNA, 
electroporation only control (EPC), or left untreated (C), and then infected 
with HIV. Increased proviral DNA was evident in cells depleted of 
  APOBEC3G. Representative experiment, n = 3.JEM VOL. 203, January 23, 2006  45
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that APOBEC3G also blocks hepatitis B virus replication, 
pointing to a broader antiviral profi  le (18). Moreover, the evi-
dence that multiple APOBEC3 family proteins are inducible 
by IFN-α indicates the potential for additional elements in the 
regulatory control of the viral life cycle. With the recent rec-
ognition of several new host cell–associated proteins controlled 
by and/or required for HIV infection, such as p21 and annexin 
II (27, 28), as well as those that represent potent opposition to 
HIV infection (TRIM5α, APOBEC3G, and lentivirus sus-
ceptibility-1; references 1 and 29), new classes of inhibitors 
may emerge as future antiviral candidates.
MATERIALS AND METHODS
Isolation and culture of human blood monocytes. Human peripheral 
blood mononuclear cells, obtained by leukapheresis of normal volunteers at 
the Department of Transfusion Medicine (NIH), were diluted in endotoxin-
free PBS without Ca2+ and Mg2+ (BioWhittaker) and separated by density 
centrifugation on lymphocyte sedimentation medium (Organon Teknika 
Corp.) at 400 g for 30 min. The monocytes in the mononuclear cell layer 
were enriched by elutriation (27, 28) and plated at 1.5 × 106/ml per well in 
48-well plates or 6 × 106/2 ml per well in 6-well plates (Corning) in DMEM 
(BioWhittaker) with antibiotics and glutamine for 3 h, followed by the addi-
tion of 10% FCS. Adherent monocytes were cultured for 7–10 d to enable 
diff  erentiation into monocyte-derived macrophages.
Infection of macrophages with M-tropic HIV-1. Unless indicated oth-
erwise, adherent macrophages were incubated with HIV-1BaL(HIV) at 1–2 × 
103/TCID50/ml (Advanced Biotechnologies, Inc.) in DMEM containing 
10% FCS for 2 h at 37°C. After infection, cells were washed with PBS three 
times and cultured in DMEM containing 10% FCS for up to 14 d (27, 28). 
IFN-α and IFN-γ (National Cancer Institute-Frederick Cancer Research 
and Development Center [NCI-FCRDC]) were added once at the indi-
cated concentrations or every 2–3 d. To measure viral infectivity, superna-
tants (200 μl) were collected at the indicated intervals and replaced with 
fresh medium. Infection was measured by supernatant p24 using HIV-1 p24 
ELISA kits (PerkinElmer) with data presented as mean ± SD and by nested 
PCR of extracted DNA as described previously (27, 28). PCR product from 
the second amplifi  cation was visualized by ethidium bromide staining after 
agarose gel electrophoresis.
RNA isolation and analysis. 6 × 106 macrophages cultured in six-well 
plates were treated with 1–100 ng/ml IFN-α and/or 1mM 2-AP (Biomol) 
for the times indicated. Total RNA was extracted using RNeasy Total 
RNA kit (QIAGEN). For RT-PCR, GeneAmp RNA PCR kit (Perkin 
Elmer, Branchburg, NJ) was used according to protocol. A total of 0.15–0.3 μg
RNA from each sample was used for fi   rst-strand cDNA synthesis. The 
cDNA was then divided and used for PCR amplifi  cation of APOBEC3G 
and other APOBEC3 family genes. PKR and GAPDH were used as con-
trols. All PCRs were performed by 30-cycle amplifi  cation, except that 25 
cycles were used for GAPDH (94°C for 4 min, followed by 30 cycles at 
94°C for 30 s, 55°C for 3 s, 72°C for 30 s, and fi  nally extension at 72°C 
for 10 min). Primers were as follows: APOBEC3A: 5′-T  T  C  T  T  T  G  C  A  G  T  T-
G  G  A  C  C  C  G  G  -3′ (forward), 5′-C  T  C  A  T  C  T  A  G  T  C  C  A  T  C  C  C  A  G  G  -3′ (re-
verse); APOBEC3B: 5′-T  G  G  T  C  G  G  A  G  C  T  A  C  A  C  T  T  G  G  C  -3′ (forward), 
5′-C  A  G  A  C  A  G  G  A  A  T  T  C  G  G  C  C  A  G  C  -3′ (reverse); APOBEC3C: 5′-C  T  T-
C  C  T  C  T  C  T  T  G  G  T  T  C  T  G  C  G  -3′ (forward), 5′-C  C  A  T  G  A  T  C  T  C  C  A  C  A  G  C-
G  A  C  C  -3′ (reverse); APOBEC3F: 5′-T  A  C  G  C  A  A  A  G  C  C  T  A  T  G  G  T  C  G  G  -3′ 
(forward), 5′-G  C  T  C  C  A  A  G  A  T  G  T  G  T  A  C  C  A  G  G  -3′ (reverse); APOBEC3G: 
5′-T  T  A  C  C  T  G  C  T  T  C  A  C  C  T  C  C  T  G  G  -3′ (forward), 5′-T  C  A  T  C  T  A  G  T  C  C-
A  T  C  C  C  A  G  G  G  -3′ (reverse); PKR: 5′-G  C  C  T  T  T  T  C  A  T  C  C  A  A  A  T  G  G  A  A-
T  T  C  -3′ (forward), 5′-G  A  A  A  T  C  T  G  T  T  C  T  G  G  G  C  T  C  A  T  G  -3′ (reverse); 
and GAPDH: 5′-C  C  T  T  G  G  A  G  A  A  G  G  C  T  G  G  G  G  -3′ (forward), 5′-C  A  A  A-
G  T  T  G  T  C  A  T  G  G  A  T  G  A  C  C  -3′ (reverse).
For real-time PCR, cDNA was prepared using the GeneAmp RNA PCR 
Core kit (Applied Biosystems), and cDNA corresponding to 7.5 ng RNA was 
used for each reaction in triplicate. The primers for APOBEC3G and GAPDH 
and the FAM dye-labeled probes were from Applied Biosystems. PCR reac-
tions (15 s at 95°C for melting and 1 min at 60°C for annealing/extending; a 
total of 40 cycles) were conducted with the Real Time PCR System 7500 
(Applied Biosystems). Gene expression was determined using the relative quantifi  -
cation: ∆∆CT = (CT Target − CT GAPDH)Test − (CT Target − CT GAPDH)Control. CT 
is the fractional cycle number that reaches a fi  xed threshold, CTest is the test of 
interest, and CControl is the reference control (RNA from 2-h untreated cells). 
∆CT is the diff  erence between gene expression in treated cells and reference 
control cells. The fold increase was calculated using 2-∆∆CT (30).
Western blot for APOBEC3G protein. Macrophages were treated with 
or without IFN-α, IFN-γ, and/or 2-AP for the times indicated, and cells 
were lysed with ice-cold buff  er containing 10 mM Hepes, pH 7.9, 10 mM 
KCl, and 0.1 mM EDTA, and 0.1 mM EGTA, 0.5 mM PMSF, 1 mM DTT, 
and 0.5% NP-40. 15–75 μg protein was used for electrophoresis (10% poly-
acrylamide gel) and blotted onto nitrocellulose membranes. After blocking 
with 5% milk in Tris-buff  ered saline with 0.05% Triton X-100 (TBS-T), 
membranes were probed with monoclonal anti-APOBEC3G at 1:1,000 (Im-
munodiagnostics) or polyclonal anti-PKR at 1:1,000 (Cell Signaling) at 4°C 
overnight. Membranes were washed with TBS-T three times for 10 min, 
  followed by secondary antibodies conjugated with horseradish peroxidase 
(Santa Cruz Biotechnology, Inc.), and detected by chemiluminescence (Pierce 
Chemical Co.). A similar protocol was followed for detection of APOBEC3G 
in cells treated with 100 ng/ml IFN-γ, TNF-α, IL-1β, IL-8, MCP-1, or 
RANTES (NCI-FCRDC) or 10 ng/ml TGF-β (R&D Systems) for 20 h.
siRNA inhibition of APOBEC3G. Monocytes (30 × 106 cells) were 
treated with 36 μl siRNA (20 nM) or siRNA (control; QIAGEN) in 300 μl 
Dendritic Nucleofector Solution (Amaxa Biosystems) or siRNA buff  er only 
at room temperature. APOBEC3G siRNA was synthesized based on the se-
quence r(C  G  G  U  C  A  A  G  A  U  G  G  A  C  C  A  G  C  A  )dTdT/r(U  G  C  U  G  G  U  C  C  A  U-
C  U  U  G  A  C  C  G  )dAdG. 100-μl aliquots were added to a cuvette for electropora-
tion using the U-02 program (27, 28). After electroporation, the cells from 
three replicate cuvettes were pooled and resuspended in 3 ml RPMI before 
0.2 ml (2 × 106) was added into a 24-well plate containing 1 ml RPMI pre-
incubated in a humidifi  ed 37°C/5% CO2 incubator for 30 min and incu-
bated for 3 h. The medium was changed to complete DMEM (1.5 ml/well), 
and the cells were cultured for 6 d before infection with HIV and/or treat-
ment with 0.1–10 ng/ml IFN-α.
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